All Updates

All Updates

icon
Filter
Funding
Avicenna Biosciences raises USD 6 million in debt financing to accelerate drug development
AI Drug Discovery
Feb 25, 2024
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Feb 25, 2024

Avicenna Biosciences raises USD 6 million in debt financing to accelerate drug development

Funding

  • Durham-based AI drug developer Avicenna Biosciences has secured USD 6 million in debt financing according to a Securities and Exchange Commission (SEC) filing.

  • The funds will fuel the company’s ongoing drug discovery and development process to treat neurodegenerative diseases.

  • Founded in 2020, Avicenna Biosciences leverages machine learning-enhanced medicinal chemistry for drug development. This approach is designed to streamline the lead-to-candidate optimization process for small-molecule drug development. Currently, the company is focused on developing a treatment for Amyotrophic Lateral Sclerosis, a progressive neurodegenerative disease.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.